Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor

Experimental Biology and Medicine

Volumn 237, Issue 8, 2012, Pages 973-984

  Maroni, Laís de Carvalho ^a   Silveira, Amanda Cardoso de Oliveira ^a   Leite, Elaine Amaral ^b   Melo, Marília Martins ^b   Ribeiro, Ana Flávia de Carvalho ^b,c   Cassali, Geovani Dantas ^d   de Souza, Cristina Maria ^d   Souza Fagundes, Elaine Maria ^b   Caldas, Iramaya Rodrigues ^e   Araújo, Márcio Sobreira Silva ^a   Martins Filho, Olindo Assis ^a   de Oliveira, Mônica Cristina ^b   Teixeira Carvalho, Andréa ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^d Laboratório de Patologia Comparada   (Brazil)

^e UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Antitumor effectiveness; Cisplatin; Ehrlich ascitic tumor; Intraperitoneal; Long circulating and pH sensitive liposomes

Indexed keywords

CISPLATIN; CREATININE; LIPOSOME; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BLOOD SAMPLING; BONE MARROW TOXICITY; CANCER STAGING; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; EHRLICH ASCITIC TUMOR; FEMALE; GRANULOCYTE; HEMATOLOGY; HISTOPATHOLOGY; IMMUNE RESPONSE; KIDNEY; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; LIVER; MICROSCOPY; MOUSE; NONHUMAN; SPLEEN; THROMBOCYTE COUNT; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HISTOCYTOCHEMISTRY; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIPOSOMES; LIVER; MICE; SPLEEN; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84865344216     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.011432     Document Type: Article

References (25)

1. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm 2002;54:1-7
2. Kumagai S, Sugiyama T, Nishida T, Ushijima K, Yakushiji M. Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres. Jpn J Cancer Res 1996;87:412-7
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
4. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 1985;20:1-9
5. Kaplun A. Liposomes: what can be better? Cell Mol Biol Lett 2005;10:28-30
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84
7. Araújo JGC, Mota LG, Leite EA, Maroni LC, Wainstein AJA, Coelho LGV, Savassi-Rocha PR, Pereira MT, Teixeira-Carvalho A, Cardoso VN. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice. Exp Biol Med (Maywood) 2011;236:808-15
8. Leite EA, Giuberti CS, Wainstein AJA, Wainstein APDL, Coelho LGV, Lana AMQ, Savassi-Rocha PR. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci 2009;84:641-9
9. Carvalho Júnior AD, Vieira FP, Melo VJ, Lopes MTP, Silveira JN, Ramaldes GA, Garnier-Suillerot A, Pereira-Maia EC. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res 2007;40:1149-57
10. Lecoeur H, Prévost MC, Gougeon ML. Oncosis is associated with exposure of phosphatidylserine residues on the outside layer of the plasma membrane: a reconsideration of the specificity of the annexin V/ propidium iodide assay. J Comp Neurol 2001;72:65-72
11. Del Puerto HL, Martins AS, Milsted A, Souza-Fagundes EM, Braz GF, Hissa B, Andrade LO, Alves F, Rajão DS, Leite RC, Vasconcelos AC. Canine distemper virus induces apoptosis in cervical tumor derived cell lines. Virol J 2011;8:334
12. Phillips WT, Medina LA, Klipper R, Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. Pharmacology 2002;303:11-6
13. Burger KNJ, Staffhorst RWHM, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 2002;8:81-4
14. Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9
15. Muggia F, Fojo T. Platinums: extending their therapeutic spectrum. J Chem 2004;16:77-82
16. Verçosa-Júnior D, Souza-Fagundes EM, Cassali GD, Ribeiro EL, Zani CL. Efeito do miriadenolídeo isolado de Alomia myriadenia (Asteraceae) sobre o tumor de Ehrlich ascítico no camundongo. Arq Bras Med Vet Zootecnia 2006;58:788-98
17. Velinova MJ, Staffhorst RWHM, Mulder WJM, Dries AS, Jansen BAJ, Kruijff BD, Kroon AIPM. Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim Biophys Acta 2004;1663:135-42
18. Mizumura Y, Matsumura Y, Hamaguchi T, Nishiyama N, Kataoka K, Kawaguchi T, Hrushesky WJM, Moriyasu F. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 2001;92:328-36
19. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977-83
20. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003;10:1663-82
21. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM. Original article with inoperable head and neck cancer. Ann Oncol 2001;12:493-6
22. De Oliveira MC, Boutet V, Fattal E, Boquet D, Grognet JM, Couvreur P, Deverre JR. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sci 2000;67:1625-37
23. Júnior ADC, Mota LG, Nunan EA, Wainstein AJA, Wainstein APDL, Leal AS, Cardoso VN. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007;80:659-64
24. Asna N, Lewy H, Ashkenazi IE, Deutsch V, Peretz H, Inbar M, Ron IG. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. Life Sci 2005;76:1825-34
25. Working P, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z, Turner N. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998;46:155-65